For the year ending 2025-12-31, AGIO made $54,028K in revenue. -$412,781K in net income. Net profit margin of -764.01%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Total product revenue, net | 54,028 | |||
| Cost of sales | 6,345 | |||
| Research and development | 339,535 | |||
| Total selling, general and administrative expenses | 180,280 | |||
| Total operating expenses | 526,160 | |||
| Loss from operations | -472,132 | |||
| Gain on sale of contingent payments | 0 | |||
| Milestone payment from gain on sale of oncology business | 0 | |||
| Interest income, net | 56,379 | |||
| Other income, net | 1,956 | |||
| Net (loss) income before taxes | -413,797 | |||
| Income tax (benefit) expense | -1,016 | |||
| Net (loss) income | -412,781 | |||
| Net income (loss) per share - basic (in usd per share) | -7.12 | |||
| Net income (loss) per share - diluted (in usd share) | -7.12 | |||
| Weighted-average number of common shares used in computing net income (loss) per share basic (in shares) | 57,972,004 | |||
| Weighted-average number of common shares used in computing net income (loss) per share diluted (in shares) | 57,972,004 | |||
AGIOS PHARMACEUTICALS, INC. (AGIO)
AGIOS PHARMACEUTICALS, INC. (AGIO)